Cyclic peptides have great potential as therapeutic agents and research tools. However, their applications against intracellular targets have been limited, because cyclic peptides are generally impermeable to the cell membrane. It was previously shown that fusion of cyclic peptides with a cyclic cell-penetrating peptide resulted in cell-permeable bicyclic peptides that are proteolytically stable and biologically active in cellular assays. In this work, we tested the generality of the bicyclic approach by synthesizing a combinatorial library of 5.7 × 10<sup>6</sup> bicyclic peptides featuring a degenerate sequence in the first ring and an invariant cell-penetrating peptide in the second ring. Screening of the library against oncoprotein K-Ra...
Protein–protein interactions represent a new class of exciting but challenging drug targets, because...
The cell membrane has polar and negative charged characteristics and separates the inside of cells f...
The development of peptide inhibitors against intracellular targets depends upon the dual challenge ...
ABSTRACT: Cyclic peptides have great potential as therapeu-tic agents and research tools. However, t...
Peptides are emerging as promising therapeutics due to their inhibitory affinity towards protein-pro...
Macrocyclic peptides are capable of binding to flat protein surfaces such as the interfaces of prote...
Cyclic peptides have great potential as therapeutic agents and research tools but are generally impe...
Aberrant Ras signalling drives 30% of cancers and inhibition of Rho family small-GTPase signalling h...
The Ras subfamily of small GTPases is mutated in ∼30% of human cancers and represents compelling yet...
This is a review of approaches to the design of peptides and small molecules that selectively block ...
Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. Thi...
Abstract P110α is a member of the phosphoinositide 3-kinase (PI3K) enzyme family that functions down...
Several protein tyrosine kinases and the signaling pathways in which they participate have emerged a...
Prior work has indicated that preventing Cdc42 interacting with its downstream effector proteins can...
Oncogenic RAS proteins are important for driving tumour formation, and for maintenance of the transf...
Protein–protein interactions represent a new class of exciting but challenging drug targets, because...
The cell membrane has polar and negative charged characteristics and separates the inside of cells f...
The development of peptide inhibitors against intracellular targets depends upon the dual challenge ...
ABSTRACT: Cyclic peptides have great potential as therapeu-tic agents and research tools. However, t...
Peptides are emerging as promising therapeutics due to their inhibitory affinity towards protein-pro...
Macrocyclic peptides are capable of binding to flat protein surfaces such as the interfaces of prote...
Cyclic peptides have great potential as therapeutic agents and research tools but are generally impe...
Aberrant Ras signalling drives 30% of cancers and inhibition of Rho family small-GTPase signalling h...
The Ras subfamily of small GTPases is mutated in ∼30% of human cancers and represents compelling yet...
This is a review of approaches to the design of peptides and small molecules that selectively block ...
Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. Thi...
Abstract P110α is a member of the phosphoinositide 3-kinase (PI3K) enzyme family that functions down...
Several protein tyrosine kinases and the signaling pathways in which they participate have emerged a...
Prior work has indicated that preventing Cdc42 interacting with its downstream effector proteins can...
Oncogenic RAS proteins are important for driving tumour formation, and for maintenance of the transf...
Protein–protein interactions represent a new class of exciting but challenging drug targets, because...
The cell membrane has polar and negative charged characteristics and separates the inside of cells f...
The development of peptide inhibitors against intracellular targets depends upon the dual challenge ...